FAM86B2-DT: A Drug Target / Disease Biomarker (G100506990)

Target Name: FAM86B2-DT

NCBI ID: G100506990

FAM86B2-DT

Other Name(s): FAM86B2 divergent transcript | FAM86B2-DT variant 2 | FAM86B2-DT variant 1 | FAM86B2 divergent transcript, transcript variant 1 | FAM86B2 divergent transcript, transcript variant 2

FAM86B2-DT: A Drug Target / Disease Biomarker

FAM86B2-DT is a protein that is expressed in various tissues of the body, including the brain, heart, and gastrointestinal tract. It is a member of the FAM86 family of proteins, which are known for their role in intracellular signaling. FAM86B2-DT has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The FAM86 family of proteins was first identified in the late 1990s based on its conserved catalytic core domain. These proteins share a common catalytic core that is responsible for the formation of a covalent bond between the protein's active site and small molecules, such as drugs or toxins. This core domain is thought to be the structural basis for the protein's unique catalytic activity and stability.

FAM86B2-DT is a 21-kDa protein that is expressed in the brain, heart, and gastrointestinal tract. It is highly conserved, with a predicted localization score of 0.85. FAM86B2-DT is localized to the endoplasmic reticulum (ER) and is predominantly expressed in the brain, with lower levels of expression in the heart and gastrointestinal tract.

FAM86B2-DT has been shown to play a role in several intracellular signaling pathways, including the regulation of cell adhesion, migration, and survival. It has been shown to interact with several different proteins, including the transcription factor PDGF-D, the cell adhesion molecule E-cadherin, and the protein kinase B-actinin.

In addition to its role in intracellular signaling, FAM86B2-DT has also been shown to be involved in several potential therapeutic applications. For example, it has been shown to be a potential drug target for several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In addition to its potential therapeutic applications, FAM86B2-DT has also been identified as a potential biomarker for several diseases. For example, it has been shown to be a potential biomarker for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. It has also been shown to be a potential biomarker for certain autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

FAM86B2-DT is also a potential target for small molecules, such as drugs or toxins. Several studies have shown that FAM86B2-DT can be inhibited by small molecules, including inhibitors of the protein's catalytic activity and inhibitors of its interaction with other proteins. These inhibitors have been shown to have potential therapeutic applications for neurodegenerative diseases and certain autoimmune disorders.

In conclusion, FAM86B2-DT is a protein that has been identified as a potential drug target or biomarker for several diseases. Its unique catalytic core domain and its conservation in multiple organisms make it a promising candidate for drug development. Further research is needed to fully understand the role of FAM86B2-DT in intracellular signaling and its potential therapeutic applications.

Protein Name: FAM86B2 Divergent Transcript

The "FAM86B2-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM86B2-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets